| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 144/A |
| 13 Nov 2026 | 144/A |
| 12 Nov 2026 |
Form 4: Torti Frank, President and Vant Chair
Disposed of 392,052 shares (Other Transaction) ($16M) · Disposed of 392,048 shares (Other Transaction) ($16.4M) · Disposed of 392,043 shares (Other Transaction) ($15.9M) · 1 more |
| 12 Nov 2026 |
Form 4: Gline Matthew, Director
Disposed of 58,331 shares (Other Transaction) ($2.38M) · Disposed of 48,988 shares (Other Transaction) ($2.05M) · Disposed of 48,988 shares (Other Transaction) ($1.98M) · 1 more |
| 12 Nov 2026 |
Form 4: Sukhatme Mayukh, Director
Disposed of 59,034 shares (Other Transaction) ($2.41M) · Disposed of 53,205 shares (Other Transaction) ($2.22M) · Disposed of 53,205 shares (Other Transaction) ($2.15M) · 1 more |
| 12 Nov 2026 |
Form 4: Pulik Richard, CFO
Received 125,000 shares by exercise or conversion ($481K) · Sold 125,000 shares ($5.15M) · Received 127,365 shares by exercise or conversion ($490K) · 1 more |
| 12 Nov 2026 |
Form 4: Venker Eric, President & Immunovant CEO
Sold 187,943 shares ($7.62M) |
| 12 Nov 2026 | 144 |
| 10 Nov 2026 | 144/A |
| 10 Nov 2026 | 144/A |
| 10 Nov 2026 | 144/A |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
BASEL, Switzerland and LONDON and NEW YORK, November 9, 2026 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2026, and provided a business update. |
| 05 Nov 2026 |
Form 4: Venker Eric, President & Immunovant CEO
Sold 200,000 shares ($7.26M) |
| 05 Nov 2026 | SCHEDULE 13G/A |
Loading...